Nilotinib System Suitability Mixture

NA

4-Methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzoic acid and 4-Methyl-N-[3-(5-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2- yl]amino}benzamide and 4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzamide hydrochloride monohydrate and N-[3-(1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzamide and N-[3-(4-Ethyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzamide and Methyl 4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzoate; A mixture containing Nilotinib (major component), Nilotinib methyl ester, Nilotinib acid, Nilotinib isomer, Desmethyl Nilotinib, and Nilotinib ethyl homolog (USP);